ALT

Altimmune
NASDAQ

实时行情|Nasdaq Last Sale

1.690
0.000
0.00%
盘前: 1.690 0 0.00% 09:25 02/27 EST
开盘
--
昨收
1.730
最高
--
最低
--
成交量
1.15万
成交额
--
52周最高
5.94
52周最低
1.510
市值
3,763.63万
市盈率(TTM)
-0.3903
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ALT价格均价为7.20,最高价位7.20,最低价为7.20。

EPS

ALT 新闻

更多
  • Altimmune to Present at the Cowen 40th Annual Health Care Conference
  • GlobeNewswire · 02/19 21:30
  • Altimmune (ALT) Presents At BIO CEO & Investor Conference 2020 - Slideshow
  • Seeking Alpha - Article · 02/11 17:16
  • Altimmune: On The Sidelines For Wuhan Coronavirus Crisis
  • Seeking Alpha - Article · 02/07 20:07
  • Altimmune to Present at Upcoming Investor and Scientific Conferences
  • GlobeNewswire · 02/04 12:00

所属板块

生物技术和医学研究
+1.71%
制药与医学研究
+0.43%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

ALT 简况

Altimmune Inc is a clinical-stage immunotherapeutics company. The Company is focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company’s product candidates include ALT-801, HepTcell, ALT-702, NasoVAX and NasoShield. HepTcell is a synthetic peptide immunotherapeutic candidate designed to break immune tolerance in chronic Hepatitis B infection. ALT-702, a TLR7/8 agonist conjugate, is a tumor immunostimulant product candidate that has the potential to safely elicit or improve immune responses in a variety of cancer indications. NasoVAX, its influenza vaccine candidate that stimulate multiple arms of the immune system and offers the potential to stop the infection and the spread of flu, while being easier to administer through an intranasal spray. NasoShield is an intranasal anthrax vaccine candidate that is designed to provide more rapid and stable protection than the only approved anthrax vaccine.
展开

微牛提供Altimmune Inc(NASDAQ-ALT)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ALT股票新闻,以帮助您做出投资决策。